Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 4/20 | 0.51 |
| ▸ | CA2 | P00918 | 4/20 | 0.51 |
| ▸ | ACHE | P22303 | 4/20 | 0.51 |
| ▸ | DRD3 | P35462 | 7/20 | 0.49 |
| ▸ | DRD2 | P14416 | 6/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 4/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 2/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16252317 | 1.00 | OPRK1 (0.57) | OPRK1CA1CA2ACHEDRD3 | |
| SCHEMBL345292 | 0.93 | DRD3 (0.57) | OPRK1CA1CA2ACHEDRD3 | |
| SCHEMBL345291 | 0.93 | DRD3 (0.57) | OPRK1CA1CA2ACHEDRD3 | |
| SCHEMBL9370418 | 0.85 | DRD2 (0.46) | OPRK1CA1CA2ACHEDRD3 | |
| SCHEMBL15961988 | 0.85 | OPRK1 (0.56) | OPRK1CA1CA2ACHEDRD3 | |
| SCHEMBL18983559 | 0.82 | OPRK1 (0.49) | OPRK1CA1CA2ACHEDRD3 | |
| SCHEMBL4621176 | 0.81 | BRD4 (0.44) | OPRK1FAAH | |
| SCHEMBL21063897 | 0.81 | FAAH (0.40) | FAAH | |
| SCHEMBL9215130 | 0.81 | CYP1A2 (0.41) | FAAH | |
| SCHEMBL2232699 | 0.81 | ALDH1A1 (0.56) | DRD3FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0617109-B1 | Liquid crystal material, liquid crystal composition and liquid crystal element | MITSUI PETROCHEMICAL IND (JP) | 1997-09-17 | — | — | EP | claimed |
| US-5422039-A | Having a chiral center-containing a tetralinylene ring as well as a second chiral center; cells having high temperature operating range; high switching speed, low voltage and stable contrast | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1995-06-06 | — | — | US | claimed |
| EP-0617109-A1 | Liquid crystal material, liquid crystal composition and liquid crystal element | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1994-09-28 | — | — | EP | claimed |
| JP-6025098-A | — | — | None | — | — | JP | disclosed |
| JP-6009500-A | — | — | None | — | — | JP | disclosed |
| JP-5255193-A | — | — | None | — | — | JP | disclosed |
| JP-7224005-A | — | — | None | — | — | JP | disclosed |
| US-10894040-B2 | S1P modulating agents | BIOGEN MA INC. (US) | 2021-01-19 | — | — | US | disclosed |
| US-10894040-B2 | S1P modulating agents | BIOGEN MA INC. (US) | 2021-01-19 | — | — | US | disclosed |
| EP-3660010-A1 | S1P MODULATING AGENTS | Biogen MA Inc. (US) | 2020-06-03 | — | — | EP | disclosed |
| EP-3660010-A1 | S1P MODULATING AGENTS | Biogen MA Inc. (US) | 2020-06-03 | — | — | EP | disclosed |
| JP-H069500-A | TETRALIN COMPOUND, LIQUID CRYSTAL MATERIAL, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL ELEMENT | MITSUI PETROCHEM IND LTD | 1994-01-18 | — | — | JP | disclosed |
| EP-0566379-A2 | Tetralin compound, liquid crystal material, liquid crystal composition and liquid crystal element | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1993-10-20 | — | — | EP | disclosed |
| EP-0566380-A2 | Carboxylic acid ester compound, liquid crystal material, liquid crystal compositions and liquid crystal element | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1993-10-20 | — | — | EP | disclosed |
| JP-H05255193-A | CARBOXYLIC ACID ESTER COMPOUND, LIQUID CRYSTAL MATERIAL, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL ELEMENT | MITSUI PETROCHEM IND LTD | 1993-10-05 | — | — | JP | disclosed |
| EP-0549347-A1 | Novel carboxylate compounds, liquid crystal materials, liquid crystal compositions and liquid crystal elements | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1993-06-30 | — | — | EP | disclosed |
| EP-0465048-A2 | Carboxylic acid ester compound, liquid crystal compound, liquid crystal composition, liquid crystal element and light modulation method | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1992-01-08 | — | — | EP | disclosed |
| US-4530919-A | A 1,2,3,4-tetrahydronaphthalene carboxylic acid | PFIZER INC. (US) | 1985-07-23 | — | — | US | disclosed |
| US-4374148-A | HYPOGLYCEMIC AGENTS | PFIZER INC. (US) | 1983-02-15 | — | — | US | disclosed |
| US-4305955-A | ORAL HYPOGLYCEMIC AGENTS, CHROMAN-4-CARBOXYLIC ACID OR THIOCHROMAN-4-CARBOXYLIC ACID | PFIZER INC. (US) | 1981-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10894040-B2 | S1P modulating agents | S1PR2, S1PR1, S1PR3 | OPRK1 751/4885CA1 4115/4885CA2 2230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.